Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Hoosier News Dispatch.
May 2025
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | |||
5 | 6 | 7 | 8 | 9 | 10 | 11 |
12 | 13 | 14 | 15 | 16 | 17 | 18 |
19 | 20 | 21 | 22 | 23 | 24 | 25 |
26 | 27 | 28 | 29 | 30 | 31 |
June 2025
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1 | ||||||
2 | 3 | 4 | 5 | 6 | 7 | 8 |
9 | 10 | 11 | 12 | 13 | 14 | 15 |
16 | 17 | 18 | 19 | 20 | 21 | 22 |
23 | 24 | 25 | 26 | 27 | 28 | 29 |
30 |
July 2025
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | |
7 | 8 | 9 | 10 | 11 | 12 | 13 |
14 | 15 | 16 | 17 | 18 | 19 | 20 |
21 | 22 | 23 | 24 | 25 | 26 | 27 |
28 | 29 | 30 | 31 |
Press releases published on May 12, 2025

All Pro Audio Visual Partners With Dreyer & Reinbold Racing, For The 109th Running Of The Indianapolis 500
APAV announces continued partnership that includes sponsorship of the Indy 500 in 2025. INDIANAPOLIS, IN, UNITED STATES, May 12, 2025 /EINPresswire.com/ -- All Pro Audio Visual (APAV), an audio visual rental and production company, announces a continued …

Hallador Energy Company Reports First Quarter 2025 Financial and Operating Results
– Q1 Total Revenue up 6% YoY to $117.8 Million – – Q1 Net Income up Materially YoY to $10.0 Million or $0.23 Earnings per Share – – Q1 Operating Cash Flow up ~2x YoY to $38.4 Million – – Q1 Adjusted EBITDA up ~3x YoY to $19.3 Million – TERRE HAUTE, Ind., …

NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today …

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities …